Processa Pharmaceuticals, Inc.

PCSA

US74275C3043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:30:00 05/07/2024 BST			5-day change	1st Jan Change
1.73 ^USD	-4.42%		-22.77%	-74.15%

06-11	Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer	CI
06-07	Top Premarket Decliners	MT

Heatwurx Inc. will Change its Name to Processa Pharmaceuticals, Inc

December 08, 2017 at 05:00 am

Effective December 08, 2017, Heatwurx Inc. will change its name to Processa Pharmaceuticals, Inc.

Latest news about Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1B Dose-Escalating Trial with Ngc-Cap in Gastrointestinal Cancer	06-11	CI
Top Premarket Decliners	06-07	MT
Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-10	CI
Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research	04-30	CI
Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	04-29	CI
Certain Restricted Stock Units of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	04-29	CI
Certain Options of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	04-29	CI
Certain Common Stock of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	04-29	CI
Top Premarket Decliners	04-26	MT
Top Midday Gainers	04-25	MT
HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target	04-25	MT
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial	04-11	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	01-26	MT
Top Midday Decliners	01-26	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	01-26	MT
Processa Pharmaceuticals Prices $7 Million Common Stock Offering	01-26	MT
Sector Update: Health Care Stocks Softer Late Afternoon	01-25	MT
Top Midday Gainers	01-25	MT
Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment	01-25	DJ
Processa Pharmaceuticals, Inc. Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	01-25	CI
Processa Pharmaceuticals Proposes Equity Offering	01-22	MT
Sector Update: Health Care Stocks Steady Late Afternoon	01-19	MT
Sector Update: Health Care	01-19	MT
Processa Plans to Expand NGC-Cap Program Into Breast Cancer; Shares Soar	01-19	MT

Chart Processa Pharmaceuticals, Inc.

Duration

Period

More charts

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDAâs) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.73 USD

Average target price

6 USD

Spread / Average Target

+246.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROCESSA PHARMACEUTICALS, INC.	-74.15%	4.94M
ELI LILLY AND COMPANY	+56.89%	823B
NOVO NORDISK A/S	+39.52%	627B
JOHNSON & JOHNSON	-6.55%	353B
MERCK & CO., INC.	+15.99%	320B
ABBVIE INC.	+7.92%	295B
ASTRAZENECA PLC	+13.74%	239B
NOVARTIS AG	+13.83%	220B
ROCHE HOLDING AG	-0.49%	219B
AMGEN INC.	+7.94%	167B

Other Pharmaceuticals

Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Pharmaceuticals

Heatwurx Inc. will Change its Name to Processa Pharmaceuticals, Inc

Latest news about Processa Pharmaceuticals, Inc.

Chart Processa Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals